Herpes Zoster Reactivation After COVID-19 Vaccine with Focus on Postherpetic Neuralgia Prevention: A Case Series.
| Autor: | Chrona E; Department of Anaesthesiology, Pain Management Unit, General Hospital of Nikea, Piraeus, Greece., Tsoumani M; Department of Emergency, Pain Management Unit, General Hospital of Nikea, Piraeus, Greece., Batistaki C; Hygeia Private Hospital, Pain Management Unit, Athens, Greece. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anesthesiology and pain medicine [Anesth Pain Med] 2023 Dec 10; Vol. 13 (6), pp. e131366. Date of Electronic Publication: 2023 Dec 10 (Print Publication: 2023). |
| DOI: | 10.5812/aapm-131366 |
| Abstrakt: | Introduction: Herpes zoster (HZ), also known as shingles, is caused by the reactivation of the varicella-zoster virus (VZV). There have been several reports of HZ associated with COVID-19 vaccination, and the outcomes have varied. Case Presentation: In this report, we present 4 cases of patients who experienced HZ reactivation after receiving a COVID-19 vaccine. These individuals sought treatment at a pain management center due to postherpetic neuralgia (PHN). While HZ itself can be treated, post-herpetic neuralgia can persist for years, significantly impacting the patients' quality of life. Therefore, early recognition of this adverse effect is crucial, and patients should receive specialized analgesic support promptly to prevent the development of chronic pain. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2023, Chrona et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|